Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304
Objective: To assess efficacy and safety of once-daily 8 or 12 mg perampanel, a
noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor …
noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor …
Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures
GL Krauss, JM Serratosa, V Villanueva, M Endziniene… - Neurology, 2012 - AAN Enterprises
Objective: To evaluate the efficacy and safety of perampanel 2, 4, and 8 mg/day added to 1–
3 concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial-onset seizures …
3 concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial-onset seizures …
Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: results of randomized global phase III study 305
Purpose: To assess the efficacy and safety of once‐daily doses of perampanel 8 and 12 mg
when added to 1–3 concomitantly administered, approved antiepileptic drugs (AEDs) in …
when added to 1–3 concomitantly administered, approved antiepileptic drugs (AEDs) in …
Adjunctive perampanel in partial‐onset seizures: Asia‐Pacific, randomized phase III study
T Nishida, SK Lee, Y Inoue, K Saeki… - Acta Neurologica …, 2018 - Wiley Online Library
Objectives To evaluate the efficacy, safety, and tolerability of perampanel, a selective, non‐
competitive, α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor …
competitive, α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor …
Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies
Purpose Three phase III studies (304 [ClinicalTrials. gov identifier: NCT 00699972], 305
[NCT 00699582], 306 [NCT 00700310]) evaluated perampanel, an α‐amino‐3‐hydroxy‐5 …
[NCT 00699582], 306 [NCT 00700310]) evaluated perampanel, an α‐amino‐3‐hydroxy‐5 …
Perampanel: Does it have broad‐spectrum potential?
H Potschka, E Trinka - Epilepsia, 2019 - Wiley Online Library
This article reviews the profile of perampanel, a novel noncompetitive α‐amino‐3‐hydroxyl‐
5‐methyl‐4‐isoxazole‐propionate (AMPA) receptor antagonist, and its role as a potential …
5‐methyl‐4‐isoxazole‐propionate (AMPA) receptor antagonist, and its role as a potential …
Novel treatment options for epilepsy: focus on perampanel
V Franco, F Crema, A Iudice, G Zaccara… - Pharmacological …, 2013 - Elsevier
Perampanel is a new chemical entity recently approved in the United States (US) and
European Union (EU) as adjunctive treatment of partial-onset seizures with and without …
European Union (EU) as adjunctive treatment of partial-onset seizures with and without …
Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial …
Purpose: To evaluate safety, tolerability, and seizure outcome data during long‐term
treatment with once‐daily adjunctive perampanel (up to 12 mg/day) in patients with …
treatment with once‐daily adjunctive perampanel (up to 12 mg/day) in patients with …
Perampanel S tudy 207: long‐term open‐label evaluation in patients with epilepsy
I Rektor, GL Krauss, M Bar, V Biton… - Acta Neurologica …, 2012 - Wiley Online Library
Objectives Evaluate interim long‐term tolerability, safety and efficacy of adjunctive
perampanel, a novel α‐amino‐3‐hydroxy‐5‐methyl‐5‐isoxazolepropionic acid (AMPA) …
perampanel, a novel α‐amino‐3‐hydroxy‐5‐methyl‐5‐isoxazolepropionic acid (AMPA) …
Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: results from phase III extension study …
Objective To evaluate safety, tolerability, seizure frequency, and regional variations in
treatment responses with the AMPA antagonist, perampanel, in a large extension study …
treatment responses with the AMPA antagonist, perampanel, in a large extension study …